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Summary
QUESTIONS UNDER STUDY: Evidence-based recom-
mendations play an important role in medical decision-
making, but barriers to adherence are common. In Switzer-
land, the Swiss Medical Board (SMB) publishes evidence
reports that conclude with recommendations. We assessed
the impact of two SMB reports on service provision (2009:
Recommendation of conservative treatment as first option
for rupture of the anterior cruciate ligament of the knee;
2011: Recommendation against PSA screening for prostate
cancer).
METHODS: We performed an observational study and as-
sessed quantitative data over time via interrupted times
series analyses. The primary outcome was the quarterly
number of performed prostate-specific antigen (PSA) tests
and the annual rates of surgical ACL repair in patients with
ACL rupture. Data were adjusted for time trends and relev-
ant confounders.
RESULTS: We analysed PSA tests in 662,874 outpatients
from 2005–2013 and treatment data in 101,737 patients
with knee injury from 1990–2011.
For the number of PSA tests, the secular trend before the
intervention showed a continuous but diminishing increase
over time. A statistically significant reduction in tests was
estimated immediately after the intervention, but a later re-
turn to the trend before the intervention cannot be ruled out.
The rate of surgical ACL repair had already declined after
the late 1990s to about 55% in 2009. No relevant additional
change emerged in this secular trend after the intervention.
CONCLUSIONS: Despite some evidence of a possible
change, we did not find a sustained and significant impact
of SMB recommendations in our case study. Further mon-
itoring is needed to confirm or refute these findings.
Key words: impact evaluation; guideline; prostate-specific
antigen; PSA; anterior cruciate ligament; ACL repair;
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Introduction
Evidence-based recommendations play an important role
in medical decision-making, but barriers to adherence are
common [1–3]. Conceptual models for clinical guideline
adherence allow a better understanding of threats and suc-
cess factors for guideline adherence [1]. Such frameworks
are often based on collaboration of multidisciplinary
groups of clinicians, social-psychologists and marketing
experts, and linked to the “theory of planned behaviour”
(knowledge – attitudes – behaviour) [4].
In Switzerland, the Swiss Medical Board produces health
technology assessment (HTA) reports that conclude with
recommendations (www.medical-board.ch). In these HTA
reports, the Swiss Medical Board (SMB) examines dia-
gnostic or therapeutic services if they are controversial but
reimbursed under the Swiss social insurance scheme. To be
in line with the legal demands, reimbursed services have to
be “effective, appropriate and efficient”. Selection of HTA
topics is made according to predefined criteria (such as
high volume impact or highly debated cost-effectiveness).
So far, 12 HTA reports have been published that cover dif-
ferent services (e.g. screening via mammography; statins
for primary prevention of cardiovascular disease).
The SMB was founded in 2009 and is now active at the
Swiss national level, but is supported by the cantons and
not by the central government. The function of the SMB is
to produce HTA reports. In the Swiss health care system,
the SMB has not the legal competency to formulate man-
datory decisions, but it formulates recommendations for
clinical providers and other decision makers, as well as
providing information for the public. The SMB has no oth-
er roles, such as direct involvement in reimbursement de-
cisions. As with other HTA-agencies, such as the National
Institute for Health and Care Excellence (NICE) in Eng-
land [5, 6] or the Swedish Council on Health Technology
Assessment (SBU) [7], the SMB needs to know if their re-
commendations have any impact on clinical practice.
Thus, the funding body of the SMB commissioned an inde-
pendent impact evaluation to better understand opportunit-
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ies and possible shortcomings of SMB recommendations.
Two SMB reports were selected for impact evaluation as
case studies:
– “Rupture of the anterior cruciate ligament of the knee:
surgical or conservative treatment?” (published in
2009; updated in 2013)
– “The value of the PSA test for prostate cancer screen-
ing” (published in 2011)
Briefly, in the 2009 report about anterior cruciate ligament
(ACL) rupture, the SMB concluded that surgical and con-
servative treatments are similarly effective, but surgical
ACL repair is more costly. The SMB recommended the
conservative approach, including physical therapy and re-
moval of meniscus or cartilage tears if necessary, as the
standard treatment option for most of the ACL rupture pa-
tients [8]. In the 2011 report about prostate-specific anti-
gen (PSA) screening, the SMB’s recommendation was not
to use PSA screening for prostate cancer in men without
symptoms or without family predisposition for prostate
cancer [9].
These reports were selected for impact evaluation for a
variety of reasons: (i.) they represent a surgical and a non-
surgical clinical service of high relevance, (ii.) they cover
the therapeutic and the diagnostic (screening) domain, (iii.)
the recommendations have both been under intense debate
in the clinical community, and (iv.) a sufficiently long time
period after publication has passed for impact data to be
available.
With this paper, we report the methodological approach of
the first SMB impact evaluation and the main quantitative
findings.
Methods
Firstly, we established a Methodological Expert Group for
methodological advice and validation of results. This group
was independent from the commissioner and had no steer-
ing function. The expert group comprised clinicians (from
general practice and traumatology), experts from the social
insurance system (mandatory Swiss accident insurance
scheme), epidemiological and health services research ex-
perts (research area: guideline implementation) as well as
an expert on patient advocacy.
Figure 1
Key elements of interrupted time series design.
Adapted according to Matowe [26].
Aim of the study
We aimed to assess the impact of the two selected SMB re-
ports on the provision of services in the Swiss healthcare
system.
Outcome
We defined final impact as the number of services provided
(PSA test; ACL repair), which may be due to behaviour of
clinicians or due to the request of patients themselves. We
did not assess behaviour of health professionals via self-de-
claration in questionnaires, as this may be prone to bias if
someone does not agree with the guidelines under study.
Design
We performed a quantitative observational study and as-
sessed quantitative data over time via interrupted times
series analyses. Additional details of the study are reported
elsewhere [10].
Data collection
We used two main data sources for services provided:
For the number of PSA screening tests provided, we used
the claims data of a major Swiss health insurance company,
covering about 20% of the Swiss population (Helsana Ver-
sicherungen AG). We analysed the quarterly number of
PSA-tests from 2005–2013 in 662,874 outpatients.
For the rate of surgical repair of the ACL in patients with
ACL-rupture, we used the claims data of the mandatory
Swiss accident insurance scheme (Suva) and some private
accident insurers (SSUV database). This database covers
about 60% of the Swiss population. We analysed the rate of
ACL repair from 1990–2011 in 101,737 patients with knee
injury.
Statistics
We tested the following hypothesis: in the case of a relev-
ant impact of the respective SMB recommendation (i.e. in-
tervention), the number of PSA tests (or the rate of ACL
repair) will decline.
For the quantitative analysis, we applied a stepwise ap-
proach. First, we visually assessed a scatterplot of the num-
ber of performed services over time comprising the key ele-
ments of the interrupted time series analysis (fig. 1). We
defined the time point of intervention as the publication
date of each SMB report. We were interested in the secular
trend before intervention (slope pre) and in the secular
trend after intervention (slope post). In addition, the abso-
lute change in the number of services (change in level) at
the time of intervention was of interest.
Second, we performed a segmented regression analysis.
For the PSA analysis, the dependent variable was “number
of PSA screening tests per quarter” (explanatory variables:
“intervention” [publication of SBM report PSA, November
2011; yes/no], “co-intervention” [publication of American
Urologic Association, AUA, guidelines, November 2009;
yes/no], “population at risk for PSA screening tests” [num-
ber of insured men aged 50‒70 years], “number of inpa-
tients treated for prostate cancer” [to account for the preval-
ence of prostate cancer and thus for diagnostic PSA tests]).
For the ACL analysis, we calculated the “annual rate of
surgical ACL repair” as the “number of patients with sur-
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gical ACL repair” divided by the “number of patients with
ACL rupture”. This rate served as the dependent variable
of the regression analysis (explanatory variable: “interven-
tion” [publication of SBM ACL report, June 2009; yes/
no]).
For each regression, we modelled a time trend by a second-
order polynomial, included an interaction term for the main
intervention, and controlled for seasonal fixed effects (if
the data were collected at a higher frequency than an-
nually). Models were optimised according to AIC-statist-
ics, auto-correlation could be rejected (by a Durbin-Watson
test), and residuals were inspected for key properties such
as homoscedasticity. For inferential analysis we calculated
95% confidence intervals (CIs). No predictive intervals
were needed, as we could fully rely on empirical data. Data
were analysed with Stata SE 12 (StataCorp 2011, Stata
Statistical Software, College Station, TX).
Ethical approval was not required, as our retrospective
quantitative analysis was based on fully anonymised claims
data.
Results
Impact on number of PSA screening tests
For the PSA analysis, 34 quarterly data points from 2005
to 2013 were available (fig. 2). Data showed a relevant sea-
sonal variability, with fewer PSA tests during Q3 (July to
September), presumably as a result of summer vacations.
The secular trend before the intervention showed a continu-
ous but diminishing increase in the number of PSA tests
over time, i.e. the growth rate had declined already be-
fore the intervention (first-order coefficient: 414, 95% CI:
312‒515; second-order coefficient: –5.44, 95% CI: –8.84 ‒
–2.04]). The trend predicts an increase in PSA tests from
the previous period to the following one of 397 for
Figure 2
Prostate specific antigen (PSA) tests over time (2005–2013).
Each data point represents the number of PSA tests over 3 months
in Helsana Insurance (○ JAN-MAR; □ APR-JUN; ∆ JUL-SEP; ●
OCT-DEC). The dashed line is corrected for seasonal effects.
Vertical dashed line: Time point of SMB report released in 2011.
Blue solid trend line: Trend (95% CI) without Swiss Medical board
(SMB) recommendations up to 2013. Red solid trend line: Trend
(95% CI) after release of SMB recommendations in 2011.
2005:Q2 and of 147 for 2011:Q1 (“slope pre”, discrete
form).
During the quarter immediately after the intervention, a
statistically significant reduction in PSA tests was estim-
ated (“change in level”: –1556, 95% CI: –2679 ‒ –433]).
The secular trend during the following periods, however,
showed strong variation (coefficient of interaction between
first-order time variable and intervention: 113, 95%-CI:
–166 ‒ 392; p = 0.41). A return of the trend to its previous
path cannot be ruled out. Accordingly, the 95% CIs of the
two alternative trend functions, one including the interven-
tion and one discarding it, overlap around the beginning of
2013. Thus, the sustainability of a possible causal effect of
the intervention on the number of PSA tests remains un-
clear.
Impact on operation rates for ACL rupture
For the ACL analysis, 22 annual data points from 1990 to
2011 were available. The absolute number of patients with
ACL rupture in our data set increased between 1990 (n =
3,341) and 2011 (n = 6,942). The absolute number of sur-
gical ACL repairs increased as well (1990: n = 2,366; 2011:
n = 3,481).
However, the rate of surgical ACL repair in patients with
ACL rupture, initially reaching about 80%, declined after
the late 1990s to approximately 55% in 2009 (fig. 3). This
transition to a negative secular trend, which starts off
clearly before the intervention, results in a negative second-
order coefficient of the polynomial time trend (–0.13 per-
centage points, 95% CI: –0.16 ‒ –0.09) in combination
with a positive first-order coefficient (1.9 percentage
points, 95%-CI: 1.2‒2.7).
The rate of ACL repair continued to decline during the
two years with available data after the intervention, but the
trend after intervention is not significantly different from
the secular trend before intervention (change in level: –5.7
percentage points, 95% CI: –16.2 ‒ 4.9; p = 0.27). Thus, no
statistically significant relationship can be found between
the intervention and an intensification of the downward
time trend.
Discussion
We assessed the impact of SMB recommendations in two
case studies. Despite some evidence of a possible change
we did not find a sustained and significant impact of SMB
recommendations on annual PSA screening tests or on the
already declining rate of surgical ACL repair for ACL rup-
ture in Switzerland. However, we had only few post-inter-
vention observations and longer term data are needed to
confirm or refute the findings.
Interestingly, already before the SMB recommendations
there was a declining growth rate for PSA screening tests
in our data set. Although we adjusted the PSA data for
epidemiological trends and cointerventions, other less well
defined factors, such as the ongoing debate about the bene-
fit of PSA screening for prostate cancer, may have influen-
ced the trend before intervention.
This possibility is even more pronounced for the operation
rates due to ACL rupture. A negative secular trend with de-
creasing rates clearly started before the publication of the
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SMB report. No ACL guidelines, which might have acted
as a cointervention, exist for Switzerland. However, the in-
tensive debate about the suitable therapy for ACL rupture
over several years in the scientific community during clin-
ical symposiums and congresses may have led to changes
in clinical practice and thus a decline in operation rates for
ACL rupture already before the SMB report.
Context to existing evidence
Whereas some impact evaluations have only assessed
knowledge and attitudes [11, 12], others have focused on
case load or frequency of services (e.g. for mammography
screening [13, 14] or drug monitoring in epilepsy treatment
[15]). For example, the analysis of self-reported mammo-
graphy screening rates of women aged 40 to 49 years in the
United States showed no decline from 2005 to 2011, des-
pite the 2009 recommendation of the US Preventive Ser-
vices Task Force not to screen this age group for breast can-
cer.
We are not aware of a published impact evaluation of re-
commendations concerning surgical ACL repair. A US
study assessed the impact of a recommendation not to
screen men over 75 years with PSA tests [16]. The author
analysed data of a cancer registry and concluded that the
recommendations led to a small decline in PSA screening
rates. On the other hand, a study based on self-reported
PSA screening tests of US men showed that the effect of re-
commendations against screening had been minimal at best
[17].
The Swedish SBU agency has recently assessed the impact
of a broad spectrum of their released HTA reports [7]. A
mixed methods approach and time series data were used.
The authors assessed different outcome domains and con-
cluded that the selected HTA cases had a high impact on
clinical guidelines. Concerning the impact on clinical prac-
tice they found some SBU HTA reports with high estimated
Figure 3
Operation rates of the ruptured anterior cruciate ligament (ACL)
over time (1990–2011).
Each data point represents the annual operation rate among
patients with ruptured ACL (source: SSUV database). Vertical
dashed line: Time point of Swiss Medical Board (SMB) report
released in 2009. Blue solid trend line: Trend (95% CI) without SMB
recommendations up to 2011. Red solid trend line: Trend (95% CI)
after release of SMB recommendations in 2009.
impact (e.g. in dental care), but also some with low estim-
ated impact (e.g. for vaccination of children) [7].
Strengths and limitations of our approach
This study has for the first time assessed the impact of
SMB recommendations on the provision of services in the
Swiss healthcare system. In our model, we considered sec-
ular time trends for the quantitative analysis.
Our study has several limitations. First, it is an observa-
tional study and confounding, e.g. by cointerventions, can-
not be excluded, despite our attempt to control for several
variables. Second, the database for our impact evaluation is
small. In Switzerland, routine data for medical services are
often poorly documented or were not suitable for our pur-
poses. Thus, no data could be used, for example, from the
Swiss national statistics for in-hospital treatment, from oth-
er private accident insurances or from big medical laborat-
ories that cover the outpatient sector for PSA tests. Further-
more, ACL data were only available until 2011. Thus, only
a short time interval with two data points after intervention
in 2009 could be analysed for a possible impact on care.
Third, we had to make several assumptions, as codes for
PSA tests, International Classification of Diseases (ICD)
codes and coding of surgical procedures have been modi-
fied over the past years. However, we thoroughly scrutin-
ised data together with the data owner to minimise misclas-
sification. Finally, we only included two SMB recommend-
ations and it is unclear if our findings are transferable to
other SMB reports.
Success factors for guideline adherence
Change of clinical behaviour is subject to complex factors.
In Switzerland, for example, an intense debate about the
meaningfulness of the SMB recommendations for clinical
practice emerged [18–20].
Several success factors have been discussed in the liter-
ature to increase the impact of recommendations and one
conceptual model proposes a “knowledge-to-action” cycle
[2], which includes impact evaluations, such as our study.
Other approaches include efficient dissemination strategies
(e.g. via adapted communication strategies for target
groups); visibility of, and trust in, HTA bodies (e.g. via so-
cial marketing activities [21] and involvement of medical
opinion leaders to create effective advocates for final re-
ports [7]); involvement of citizens and patients (e.g. via co-
operation with trustworthy consumer groups [21]); active
stakeholder management and alliances with current activ-
ities against overtreatment (internationally: “choosing
wisely” [22]; in Switzerland: “smarter medicine” [23]). A
recent report of the SMB, for example, has fuelled the de-
bate about overtreatment, also internationally [24, 25].
Improved accessibility of routine care data for impact eval-
uations remains another important issue, the aim being
to close the gap from dissemination of recommendations
to generation of reliable knowledge about their impact in
practice. For example, follow-up impact assessments could
include more post-intervention data and allow more precise
impact estimations.
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Conclusions
Impact evaluation is an important tool for evidence-based
Swiss health services, as it allows a better understanding of
the magnitude of impact of clinical practice recommend-
ations. Further monitoring is needed to assess if recom-
mendations disseminated by the SMB have a relevant im-
pact on clinical practice in Switzerland.
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Figures (large format)
Figure 1
Key elements of interrupted time series design.
Adapted according to Matowe [26].
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Figure 2
Prostate specific antigen (PSA) tests over time (2005–2013).
Each data point represents the number of PSA tests over 3 months in Helsana Insurance (○ JAN-MAR; □ APR-JUN; ∆ JUL-SEP; ● OCT-DEC).
The dashed line is corrected for seasonal effects. Vertical dashed line: Time point of SMB report released in 2011. Blue solid trend line: Trend
(95% CI) without Swiss Medical board (SMB) recommendations up to 2013. Red solid trend line: Trend (95% CI) after release of SMB
recommendations in 2011.
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Figure 3
Operation rates of the ruptured anterior cruciate ligament (ACL) over time (1990–2011).
Each data point represents the annual operation rate among patients with ruptured ACL (source: SSUV database). Vertical dashed line: Time
point of Swiss Medical Board (SMB) report released in 2009. Blue solid trend line: Trend (95% CI) without SMB recommendations up to 2011.
Red solid trend line: Trend (95% CI) after release of SMB recommendations in 2009.
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